aviptadil (Investigational)

Brand and Other Names:Zyesami
  • Print

Dosing & Uses

COVID-19 (Investigational)

Investigational treatment of critically ill patients with COVID-19 who have respiratory failure

Next:

Pharmacology

Mechanism of Action

Synthetic analog of vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects

VIP binds specifically to alveolar type II cells (ATII) in lung alveolus, where it elicits anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation

Stimulates ATII cells to make surfactant that must coat the lining of the lungs in order for them to exchange oxygen with the blood; loss of surfactant causes respiratory failure and alveolar collapse, which are hallmarks of COVID-19

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.